<DOC>
	<DOCNO>NCT02316340</DOCNO>
	<brief_summary>This randomized phase II clinical trial patient histologic documentation metastatic colorectal cancer , receive local currently approve standard therapy , exclude RGF .</brief_summary>
	<brief_title>Vorinostat Plus Hydroxychloroquine Versus Regorafenib Colorectal Cancer</brief_title>
	<detailed_description>The investigator give VOR 400 mg PO daily HCQ 600 mg PO daily 4-week cycle . Patients require image 6 week prior enrollment assess measureable evidence mCRC . This randomize , control phase II clinical trial patient histological documentation metastatic colorectal cancer , receive locally currently approve standard therapy , exclude RGF . Patients randomize 1:1 RGF VOR/HCQ ( see schema ) . Also , crossover optional first progression initial therapy , base physician discretion best interest patient . If crossover do , patient study go receive treatment .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Histological documentation metastatic colorectal cancer ( mCRC ) ECOG performance status 02 Radiographical documentation metastatic disease image 6 week prior enrollment Patients mCRC must previously treat irinotecan and/or oxaliplatin and/or VEGF/EGFR therapy intolerant agent Documentation KRas mutational status Adequate hematologic , renal liver function ( i.e . absolute neutrophil count &gt; 1000/mm3 , platelet &gt; 75,000/mm3 ) ; creatinine &lt; 2 time upper limit normal ( ULN ) total bilirubin &lt; 1.5 mg/dl , ALT AST &lt; 3 time ULN , ALT AST &lt; 5 time ULN patient hepatic involvement . Able provide write informed consent Patients potential pregnancy impregnate partner must agree follow acceptable birth control method avoid conception . Women childbearing potential must negative pregnancy test within 72 hour prior receive investigational product Tumor block available previous surgery/biopsy , available , patient willing biopsy Patients receive prior therapy RGF , VOR , and/or HCQ Patients uncontrolled brain metastasis . Patients brain metastasis must asymptomatic corticosteroid least one week Due risk disease exacerbation , patient porphyria eligible Due risk disease exacerbation , patient psoriasis ineligible unless disease well control , care specialist disorder agree monitor patient exacerbation Patients previously document macular degeneration diabetic retinopathy Patients chemotherapy radiotherapy within 2 week ( 6 week nitrosoureas mitomycin C ) prior enter study . For targeted therapy , patient need clear 5 halflives Patients may receive investigational agent Patients take valproic acid another histone deacetylase inhibitor least 2 week prior enrollment History allergic reaction attribute compound similar chemical biologic composition VOR HCQ Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Major surgery significant traumatic injury occur within 21 day prior treatment QTc &gt; 500 m baseline ( average 3 determination 10 minute interval ) Gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease . Patients NGtube , Jtube , Gtube allow participate Pregnant woman exclude study vorinostat potential teratogenic abortifacient effect . For reason , woman childbearing potential men must also agree use adequate contraception ( hormonal barrier method birth control ) prior study entry duration study participation Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . Because unknown potential risk adverse event nurse infant secondary treatment mother vorinostat , breastfeed discontinue Informed Consent No study specific procedure perform without write sign informed consent document . Patients demonstrate ability understand willingness sign write informed consent document exclude study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>